Market research
PCK.AU PainChek Limited
AU AUD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 15M
- P/E ratio
- Not available
- Analyst target
- 0.08
- Dividend yield
- Not available
- Beta
- 0.47
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Health Information Services
- ISIN
- AU000000PCK6
- Market cap
- 15M
- P/E ratio
- Not available
- Analyst target
- 0.08
- Dividend yield
- Not available
- Beta
- 0.47
About
About PainChek Limited
PainChek Limited engages in the development and commercialization of mobile medical device applications that provides pain assessment for individuals in Australia, the United Kingdom, and internationally. The company provides PainChek, a clinically validated medical device that uses smartphone cameras for a facial scan then is analyzed using facial recognition AI technology to identify the presence of pain. It serves individuals that are unable to communicate with their carers. The company was formerly known as ePAT Technologies Ltd and changed its name to PainChek Limited in January 2018. PainChek Limited is based in Sydney, Australia.
Research context
PainChek Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Health Information Services
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PCK.AU discussion.
5 years, 6 months ago
PainChek Limited is currently in a long term downtrend where the price is trading 21.4% below its 200 day moving average.
From a valuation standpoint, the stock is 113.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 548.4.
PainChek Limited's total revenue sank by 30.9% to $127K since the same quarter in the previous year.
Its net income has increased by 86.3% to $-1M since the same quarter in the previous year.
Finally, its free cash flow fell by 45.0% to $-2M since the same quarter in the previous year.
Based on the above factors, PainChek Limited gets an overall score of 1/5.